Introduction
Signal 1 is a Toronto-based healthcare technology company that builds an AI Management System for health systems deploying growing portfolios of clinical, operational, and predictive artificial intelligence. Tomi Poutanen co-founded Signal 1 with Mara Lederman and serves as chief executive officer per the company about page reviewed in July 2026 — not Tom Overmeer as listed in the source CSV, which Brel could not verify on any official Signal 1 publication.
Poutanen previously co-founded Layer 6, sold to TD Bank in 2018 where he served as chief AI officer, and co-founded the Vector Institute and Radical Ventures — credentials that shape Signal 1’s thesis that healthcare AI failure is organizational and operational, not primarily algorithmic.
What the company does
Signal 1’s AIMS platform gives health system stakeholders — technical leaders, operational teams, and executives — centralized visibility into AI tools in operation or under evaluation. Capabilities include streamlined AI intake and approval workflows, automated monitoring with configurable metrics and alerting, performance optimization for generative and agentic applications, and ROI tracking against clinical, operational, and research goals described in the June 22, 2026 Mount Sinai partnership release.
Mount Sinai chief digital transformation officer Robbie Freeman stated the health system needs structure to monitor performance, safety, and impact across imaging, generative, and agent-based AI without slowing innovation — the exact problem Signal 1 positions AIMS to solve as AI portfolios diversify beyond single-vendor radiology triage deployments.
Who it serves
Signal 1 serves academic medical centers and integrated delivery networks scaling AI beyond pilot phase. Mount Sinai — encompassing seven hospital campuses and the Icahn School of Medicine — joined Inova Health (December 2025) and CHAI assurance partnerships (June 2025) in Signal 1’s 2025–2026 customer timeline. Health systems evaluating Signal 1 typically lack internal infrastructure to govern dozens of concurrent AI tools across modalities introduced at different budget cycles.
Chief AI officers and digital transformation leaders compare Signal 1 against building custom governance in ServiceNow or GRC tools — Signal 1 argues purpose-built healthcare AI management reduces time-to-oversight for generative and agentic systems with novel risk profiles.
Company background
Poutanen and Lederman founded Signal 1 after mentoring AI startups at Creative Destruction Lab, observing that health systems bought clinical AI but lacked operating models to manage portfolios for value and risk. April 2022 seed financing of $12.7 million CAD led by Inovia Capital included TD Bank Group, Geoffrey Hinton, Nadir Mohamed, and Radical Ventures per Signal 1 launch materials on its resources site.
Brel notes Signal 1’s about page references founding in 2021 while the batch CSV specifies 2022 — the April 2022 public launch and seed close align with 2022 as the operational founding year for editorial purposes.
Product and AI capabilities
AIMS integrates into existing health system infrastructure rather than replacing clinical AI models — it orchestrates governance above vendor algorithms. June 2025 CHAI assurance service provider status positions Signal 1 to evaluate third-party AI against emerging coalition frameworks, extending value beyond single-system deployments to vendor assessment workflows health procurement teams require.
Agentic AI management is Signal 1’s 2026 differentiation — Poutanen’s Mount Sinai release quote emphasizes enterprise oversight for agentic solutions raising novel governance needs as hospitals adopt autonomous workflow tools beyond predictive models with established validation playbooks.
Key developments
April 2022: Signal 1 launched with Inovia-led seed funding; Poutanen CEO. June 23, 2025: CHAI assurance service provider partnership. December 2, 2025: Inova Health AIMS selection. June 22, 2026: Mount Sinai evaluates AIMS for AI governance (signal1.ai, official source).
Why it matters
Signal 1 matters because 2026 hospital AI committees face portfolio complexity — imaging triage, ambient documentation, generative reporting, and agentic workflow tools each carry different validation and monitoring requirements. AIMS addresses the missing management layer between vendor sales and clinical adoption at scale. Signal 1 complements clinical AI vendors like Aidoc rather than competing with them — hospitals may need both algorithms and governance infrastructure.
Sector context
Signal 1 belongs in Brel’s AI in healthcare coverage under healthcare analytics and AI governance, related to revenue integrity AI like SmarterDx but focused on enterprise AI portfolio management rather than claims workflows.
Sources and references
Signal 1 Mount Sinai partnership press release (June 22, 2026) and About Us page.
- Signal 1 — Mount Sinai partnership (signal1.ai, June 22, 2026)
- Signal 1 — About Us (signal1.ai)
Reviewed July 10, 2026. Tomi Poutanen is co-founder and CEO; CSV Tom Overmeer not verified.